Geron Corporation (GERN)
NASDAQ: GERN · Real-Time Price · USD
1.420
+0.030 (2.16%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Geron Revenue
In the year 2024, Geron had annual revenue of $76.99M with 32,386.92% growth. Geron had revenue of $47.54M in the quarter ending December 31, 2024, with 206,582.61% growth.
Revenue (ttm)
$76.99M
Revenue Growth
+32,386.92%
P/S Ratio
11.91
Revenue / Employee
$336,218
Employees
229
Market Cap
904.42M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 76.99M | 76.76M | 32,386.92% |
Dec 31, 2023 | 237.00K | -359.00K | -60.23% |
Dec 31, 2022 | 596.00K | -797.00K | -57.21% |
Dec 31, 2021 | 1.39M | 1.14M | 450.59% |
Dec 31, 2020 | 253.00K | -207.00K | -45.00% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
GERN News
- 7 hours ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Accesswire
- 5 days ago - SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - Accesswire
- 6 days ago - Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 15 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - GlobeNewsWire
- 24 days ago - Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments - Seeking Alpha
- 24 days ago - Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025 - Business Wire
- 24 days ago - Biotech Stocks Q1 2025 Recap: Winners And Underperformers - Seeking Alpha
- 4 weeks ago - Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK) - Accesswire